T1	Participants 525 754	premenopausal women who had undergone primary surgery for stage I/II estrogen-receptor-positive and/or progesterone-receptor-positive breast cancer with <10 positive lymph nodes, and were scheduled for standard goserelin therapy.
T3	Participants 1396 1424	251 DFS events and 86 deaths
T2	Participants 759 947	1803 patients received goserelin (3.6 mg every 28 days) and were randomized to tamoxifen (20 mg/days) or anastrozole (1 mg/days), both with or without ZOL (4 mg every 6 months) for 3 years
T4	Participants 1639 1667	anastrozole-treated patients
